Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE

DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE

Standard Dose
5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE is listed in Drugs@FDA under application 211532 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE Form and strength TABLET; ORAL - 5MG Sponsor LUPIN LTD Submission history Latest submission status date: 2024-01-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE is listed in Drugs@FDA under application 211532 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE Form and strength TABLET; ORAL - 5MG Sponsor LUPIN LTD Submission history Latest submission status date: 2024-01-03 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE (DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE) | Drug Monograph | MedicHelpline